Lung cancer varies widely from patient to patient, and that diversity makes it hard to find effective treatments. Researchers ...

Although rheumatologists consider chimeric antigen receptor T-cell therapy “potentially transformative,” nearly 70% remain ...

The anti-tumor immune response involves a series of complex steps mediated by various immune cells and signaling molecules.

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...

Explore the complexities of modern oncology, including precision medicine, CAR T-cell therapies, and challenges in breast ...

Therapies market, valued at USD 16.7 million in 2024, is expected to register robust revenue CAGR of 44.6%.Request free copy of this report: 13, 2026- The growing incidence of autoimmune disorders ...

The market size of CGT products is expected to continue to rise by 2031 and reach $63 billion. CGTs have yielded commercial gains for several pharma companies. For example, some of the top-selling CGT ...

Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platformLehi Utah, Jan. 07, 2026 ...

Hong Kong-based biomed pioneer is at the forefront in a global race to develop cell and gene treatments for cancers and other ...

The patient with significant bone marrow involvement had complete bone morphological remission. In this patient in which 95% ...

In my short stint as a resident doctor in oncology, the overwhelming impression was one of complex and expensive treatments doing little for patient survival or quality of life. The options available ...